The association of serum S100A8-A9 levels with disease activity, radiological findings and laboratory parameters in patients with psoriatic arthritis
Abstract views: 133
/ 
PDF downloads: 51
DOI:
https://doi.org/10.26900/hsq.2803Keywords:
S100 proteins, disease activity, diagnosis, psoriasisAbstract
S100A8 and S100A9 play a crucial role in immune system functions. S100 proteins are expressed in different cell types and have important roles in regulating various cellular processes and in the haemostasis of the immune system. The aim of this study was to investigate the association between serum S100A8/S100A9 levels and disease-related variables in patients with psoriatic arthritis (PsA), healthy controls, and individuals with psoriasis. 62 PsA patients, 52 healthy controls and 54 psoriasis patients were included. Sociodemographic and clinical characteristic of the groups were recorded. Serum levels of S100A8 and S100A9 were accessed in all groups by ELISA. In the psoriasis group, the S100A8 level was statistically lower and the S100A9 level was statistically higher than in the PsA and control groups. In the PsA group, there was a statistically significant positive correlation between S100A9 level and number of tender and swollen joints and DAPSA score. In the PsA group, there was a statistically significant negative correlation between S100A8 level and number of tender joints, VAS, DAPSA and BASDAI scores. In the PsA group, there was no significant correlation between S100A8-S100A9, CRP and ESR, MSHS and PASRI radiological scores. In psoriasis patients, we found positive correlation between BMI and S100A9 levels. S100A9 level, the number of swollen and tender joints in the PsA group correlated with DAPSA. S100A9 can be used as a new molecule in the follow-up of PsA disease activity, and it may be associated with psoriasis. The lower stability of S100A8 compared to S100A9 and its susceptibility to oxidation suggest that it may not be suitable for diagnosis of PsA. The results were showed that there are limitations regarding the use of these biomarkers in routine diagnosis and follow-up.
Downloads
References
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et l. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Journal of Psoriasis and Psoriatic Arthritis. 2019;4(1):31-58. doi: 10.1177/247553031881224. DOI: https://doi.org/10.1177/2475530318812244
Talotta R, Atzeni F, Sarzi-Puttini P, Masala IF. Psoriatic arthritis: From pathogenesis to pharmacologic management. Pharmac Research. 2019;148:104394. doi: 10.1016/j.phrs.2019.104394. DOI: https://doi.org/10.1016/j.phrs.2019.104394
Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. The Lancet. 2018;391(10136):2273-84. doi: 10.1016/S0140-6736(18)30830-4. DOI: https://doi.org/10.1016/S0140-6736(18)30830-4
Tillett W, Charlton R, Nightingale A, Snowball J, Green A, Smith C, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology. 2017;56(12):2109-2113.5. doi: 10.1093/rheumatology/kex323. DOI: https://doi.org/10.1093/rheumatology/kex323
Boyd TA, Eastman PS, Huynh DH, Qureshi F, Sasso EH, Bolce R, et al. Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. Exp Rev Clin Immunol. 2020;16(3):335-41. doi:10.1080/1744666X.2020.1729129.
Esawy MM, Makram WK, Albalat W, Shabana MA. Plasma gelsolin levels in patients with psoriatic arthritis: A possible novel marker. Clin Rheumatol. 2020;39(6):1881-8. doi: 10.1007/s10067-020-04959-y. DOI: https://doi.org/10.1007/s10067-020-04959-y
Singh P, Ali SA. Multifunctional role of S100 protein family in the immune system: An update. Cells. 2022 Jul 23;11(15):2274. doi: 10.3390/cells11152274.8. DOI: https://doi.org/10.3390/cells11152274
Gonzalez LL, Garrie K, Turner MD. Role of S100 proteins in health and disease. Biochim Biophys Acta Mol Cell Res. 2020;1867(6):118677. doi: 10.1016/j.bbamcr.2020.118677. DOI: https://doi.org/10.1016/j.bbamcr.2020.118677
Congi L, Roussou E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin Exp Rheumatol. 2010;28(3):304-10.
Xia P, Ji X, Yan L, Lian S, Chen Z, Luo Y. Roles of S100A8, S100A9 and S100A12 in infection, inflammation and immunity. Immunology. 2024;171(3):365-76. doi: 10.1111/imm.13722. DOI: https://doi.org/10.1111/imm.13722
Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain. 1983;16(1):87-101. doi: 10.1016/0304-3959(83)90088-X. DOI: https://doi.org/10.1016/0304-3959(83)90088-X
Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69(8):1441-7. doi: 10.1136/ard.2009. DOI: https://doi.org/10.1136/ard.2009.122259
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286-91.
Küçükdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum. 2004;51(1):14-9. doi: 10.1002/art.20091. DOI: https://doi.org/10.1002/art.20091
McKenna SP, Doward LC, Whalley D, Tennant A, Emery P, Veale DJ. Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis. 2004;63(2):162-9. doi: 10.1136/ard.2003.006296. DOI: https://doi.org/10.1136/ard.2003.006296
Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken). 2011;63(11):64-85. doi: 10.1002/acr.20577. DOI: https://doi.org/10.1002/acr.20577
van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: A review of scoring methods. Ann Rheum Dis. 2005;64(2):61-4. doi: 10.1136/ard.2004.030809. DOI: https://doi.org/10.1136/ard.2004.030809
Lubrano E, Marchesoni A, Olivieri I, D'Angelo S, Spadaro A, Parsons WJ, et al. Psoriatic arthritis spondylitis radiology index: A modified index for radiologic assessment of axial involvement in psoriatic arthritis. J Rheumatol. 2009;36(5):1006-11. doi: 10.3899/jrheum.080491. DOI: https://doi.org/10.3899/jrheum.080491
Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-60. doi: 10.3758/BRM.41.4.1149. DOI: https://doi.org/10.3758/BRM.41.4.1149
Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175-91. doi: 10.3758/bf03193146. DOI: https://doi.org/10.3758/BF03193146
Kerschbaumer A, Smolen JS, Aletaha D. Disease activity assessment in patients with psoriatic arthritis. Best Pract Res Clin Rheumatol. 2018;32(3):401-14. doi: 10.1016/j.berh.2018.08.004.22. DOI: https://doi.org/10.1016/j.berh.2018.08.004
Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: A new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. DOI: https://doi.org/10.1111/j.1365-2036.2011.04866.x
Li SJ, Perez-Chada LM, Merola JF. TNF Inhibitor-Induced Psoriasis: Proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis. 2019;4(2):70-80. doi: 10.1177/2475530318810851. DOI: https://doi.org/10.1177/2475530318810851
Boyd TA, Eastman PS, Huynh DH, Qureshi F, Sasso EH, Bolce R, et al. Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. Expert Rev Clin Immunol. 2020;16(3):335-41. doi: 10.1080/1744666X.2020.1729129. DOI: https://doi.org/10.1080/1744666X.2020.1729129
Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 201813;18(4):e27. doi: 10.4110/in.2018.18.e27. DOI: https://doi.org/10.4110/in.2018.18.e27
Mellor LF, Gago-Lopez N, Bakiri L, Schmidt FN, Busse B, Rauber S, et al. Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. Ann Rheum Dis. 2022;81(10):1400-08. doi: 10.1136/annrheumdis-2022-222229.27. DOI: https://doi.org/10.1136/annrheumdis-2022-222229
Crowe LAN, McLean M, Kitson SM, Melchor EG, Patommel K, Cao HM, et al. S100A8 & S100A9: Alarmin mediated inflammation in tendinopathy. Sci Rep. 2019;9(1):1463. doi: 10.1038/s41598-018-37684-3. DOI: https://doi.org/10.1038/s41598-018-37684-3
Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13(9):1042-9. doi: 10.1038/nm1638. DOI: https://doi.org/10.1038/nm1638
McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H, et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem. 2005;280(50):41521-9. doi: 10.1074/jbc.M509442200. DOI: https://doi.org/10.1074/jbc.M509442200
Franz S, Ertel A, Engel KM, Simon JC, Saalbach A. Overexpression of S100A9 in obesity impairs macrophage differentiation via TLR4-NFkB-signaling worsening inflammation and wound healing. Theranostics. 2022;12(4):1659-82. doi: 10.7150/thno.67174. DOI: https://doi.org/10.7150/thno.67174
Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15. doi: 10.1136/annrheumdis-2015-207524. DOI: https://doi.org/10.1136/annrheumdis-2015-207524
Al-Bassam WW, Ad'hiah AH, Mayouf KZ. Significance of calgranulins (S100A8, S100A9 and S100A12), ferritin and toll-like receptor 4 in juvenile idiopathic arthritis children. Egyp Rheumatol. 2020;42(2):147-52. doi: 10.1016/j.ejr.2019.08.005. DOI: https://doi.org/10.1016/j.ejr.2019.08.005
Xu X, Wu WY, Tu WZ, Chu HY, Zhu XX, Liang MR, et al. Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities. Clin Rheumatol. 2013;32(10):1501-10. doi: 10.1007/s10067-013-2305-4. DOI: https://doi.org/10.1007/s10067-013-2305-4
Kim JW, Jung JY, Lee SW, Baek WY, Kim HA, Suh CH. S100A8 in serum, urine, and saliva as a potential biomarker for systemic lupus erythematosus. Front Immunol. 2022;13:886209. doi: 10.3389/fimmu.2022.886209. DOI: https://doi.org/10.3389/fimmu.2022.886209
Li B, Li G, Song Z, Zhang Z. Serum calprotectin as a promising inflammatory biomarker in psoriatic arthritis: A 1-year longitudinal study. Rheumatol Ther. 2023;10(1):149-60. doi: 10.1007/s40744-022-00501-5. DOI: https://doi.org/10.1007/s40744-022-00501-5
Oktayoglu P, Bozkurt M, Mete N, Caglayan M, Em S, Nas K. Elevated serum levels of calprotectin (myeloid-related protein 8/14) in patients with ankylosing spondylitis and its association with disease activity and quality of life. J Investig Med. 2014;62(6):880-4. doi: 10.1097/JIM.0000000000000095. DOI: https://doi.org/10.1097/JIM.0000000000000095
Elwan SA, El-Saadany HM, El-Banna HS, Ameen TE, Hay DIA, Gado SE. Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients. Egyp Rheumatol. 2021;43(3):241-5. doi: 10.1016/j.ejr.2021.03.002. DOI: https://doi.org/10.1016/j.ejr.2021.03.002
Huang J, Yin Z, Song G, Cui S, Jiang J, Zhang L. Discriminating value of calprotectin in disease activity and progression of nonradiographic axial spondyloarthritis and ankylosing spondylitis. Dis Markers. 2017;2017:7574147. doi: 10.1155/2017/7574147. DOI: https://doi.org/10.1155/2017/7574147
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Holistence Publications
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication, with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share and adapt the work with an acknowledgement of the work's authorship and initial publication in this journal.
2. Everyone who is listed as an author in this article should have made a substantial, direct, intellectual contribution to the work and should take public responsibility for it.
